Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

802.59 +5.67 (+0.71%)
Streaming Delayed Price Updated: 2:20 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
Where argenx Stands With Analysts
 
Via Benzinga
Earnings Scheduled For July 31, 2025
 
Via Benzinga
argenx Earnings Preview
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
From argenx SE
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
From Pomerantz LLP
Via GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease. 
Via Benzinga
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
From argenx SE
Via GlobeNewswire
Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention
VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional. 
Via Stocktwits
Topics Artificial Intelligence
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
From argenx SE
Via GlobeNewswire
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx Announces Results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027. 
Via Benzinga
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.